Reducing immune-suppressing drugs in liver transplant patients
Part of Digestive system clinical trials.
This study tests if some liver transplant patients can safely take lower doses of their immune-suppressing medicines, potentially reducing side effects. It uses a biomarker test to guide the treatment changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old.
- You had a liver transplant between 12 and 24 months ago.
- Your transplant was for a non-autoimmune liver disease (e.g., not autoimmune hepatitis, PBC, or PSC).
- You are currently taking a calcineurin inhibitor (like tacrolimus or cyclosporin) as part of your anti-rejection medicines.
- Your immunosuppression has been stable for at least 3 months and you have not had a rejection episode in the last 6 months.
- You have no history of chronic rejection or cirrhosis since your transplant, and your liver and kidney tests are in normal ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether switching from a standard anti-rejection medicine to a different one (everolimus) about a year after a liver transplant can help protect your new liver with fewer side effects. If you qualify, you will be monitored closely for a few years to see how well the new medicine works for you.
This study tests a new way to lower the amount of immune-suppressing medicine needed after a liver transplant. It uses special treatments before or during the transplant to help your body accept the new liver with fewer drugs, which may reduce side effects.
This study tests whether long-term liver transplant recipients (5+ years after transplant) can safely stop or reduce their immunosuppressant medications by checking for donor cells (chimerism) in the liver. If you have stable liver function and agree to a liver biopsy, you may be able to join.
This study tests whether adding the drug everolimus can safely reduce the amount of tacrolimus (an anti-rejection medicine) needed after a first liver transplant. This may help protect your kidneys while still preventing organ rejection.
This study looks at whether it is safe to stop or reduce anti-rejection medicines in children who have had a liver transplant for at least 4 years and are doing well. The goal is to see if they can live without these medicines and their side effects.
This research study tracks early signs of immune system changes in children who received a liver transplant 3–7 years ago and are doing well. By studying blood and liver samples, researchers hope to better understand how to prevent rejection and improve long-term transplant survival.
Hear when a new Liver Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.